Brainstorm Cell Therapeutics (BCLI)
(Delayed Data from NSDQ)
$0.42 USD
+0.02 (5.00%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.42 0.00 (0.00%) 6:32 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCLI 0.42 +0.02(5.00%)
Will BCLI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BCLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCLI
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
BCLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BCLI
BrainStorm Cell Therapeutics announces pricing of $4M registered direct offering
BrainStorm to sell 11.11M shares at 36c in registered direct offering
BrainStorm reached alignment with FDA on Phase 3b clinical trial for NurOwn
Brainstorm Cell Therapeutics Appoints New EVP and COO
BrainStorm appoints Haro Hartounian as COO